Have studies examined cosentyx's impact on child growth?

Short answer: There isn’t a lot of published data specifically examining cosentyx (secukinumab) and child growth.

What is known:
- There have been pediatric trials of secukinumab for conditions like juvenile idiopathic arthritis (including enthesitis-related arthritis) and for pediatric plaque psoriasis. These studies mainly report on efficacy and safety, not growth metrics.
- Growth-related outcomes (e.g., height velocity, height z-scores) are not commonly reported as primary or even secondary endpoints in these trials, so there isn’t robust published evidence showing a positive or negative effect of cosentyx on growth.
- In general, better control of inflammatory disease and reduced reliance on systemic steroids can help children grow more normally, but that is not specific to cosentyxin data.

If you want, I can:
- Look up the specific pediatric secukinumab trials and summarize whether any growth-related data were collected or reported.
- Check the latest labeling and regulatory documents in your country for any mention of pediatric growth or development data.
- Help interpret any particular study you have in mind.

Tell me the region (e.g., US, EU) and whether you’re focusing on juvenile plaque psoriasis or juvenile idiopathic arthritis, and I’ll tailor the search.